Stockreport

argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

argenx SE - American Depositary Shares  (ARGX) 
PDF Rapid disease control observed in 4/6 patients Strong PD effect correlates with improvement in PDAI score Favorable tolerability profile; Independent Data Monitoring [Read more]